India, June 22, 2021 - Sun Pharmaceutical Industries Limited, &Ldquo;Sun Pharma&Rdquo; And Includes Its Subsidiaries And/Or Associate Companies) Along With One Of Its Wholly Owned Subsidiaries Today Announced That They Have Reached An Agreement With Celgene Corporation (Celgene), A Wholly-Owned Subsidiary Of Bristol Myers Squibb, To Resolve The Patent Litigation Regarding Submission Of An Abbreviated New Drug Application (Anda) For A Generic Version Of Revlimid&Reg; (Lenalidomide Capsules) In The Us.Pursuant To The Terms Of The Settlement, Celgene Will Grant Sun Pharma A License To Celgene&Rsquo;S Patents Required To Manufacture And Sell (Subject To Usfda Approval) Certain Limited Quantity Of Generic Lenalidomide Capsules In The Us Beginning On A Confidential Date That Is Sometime After March 2022. In Addition, The License Will Also Allow Sun Pharma To Manufacture And Sell An Unlimited Quantity Of Generic Lenalidomide Capsules In The Us Beginning January 31, 2026.As A Result Of The Settlement, All Hatch-Waxman Litigation Between Sun Pharma And Celgene, Regarding The Revlimid&Reg; Patents, Will Be Dismissed. Additional Details Regarding The Settlement Are Confidential. The Agreement Is Subject To Customary Regulatory Approvals.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!